01
Cash & equivalents increased 204.6%
Cash & equivalents changed +204.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
$47.7M→$145.3MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTZEVRA THERAPEUTICS, INC.'s latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +204.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Debt changed +4.1% from the comparable as-filed period.
Inventory changed +121.0% from the comparable as-filed period.
Net income changed -88.3% from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
ZVRA · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001434647-26-000073SEC ↗4Aug 12, 2026Period Aug 10, 20260001434647-26-000070SEC ↗10-QAug 5, 2026Period Jun 30, 20260001434647-26-000068SEC ↗8-KAug 5, 2026Period Aug 5, 20260001434647-26-000067SEC ↗4Jun 23, 2026Period Jun 21, 20260001434647-26-000057SEC ↗4Jun 18, 2026Period Jun 4, 20260001434647-26-000055SEC ↗4Jun 18, 2026Period Jun 4, 20260001434647-26-000054SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 14, 2026Filed Aug 17, 2026 | Thompson RahsaanChief Legal & Compliance | Open Market SaleDirect | 42,666 | $11 | $474,774 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating income changed +123.6% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Selling, general & administrative changed -20.3% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Stock-based compensation changed +20.5% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001434647-26-000053